Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.
Mrz 2008 - J. Virol.; 82(4):1098-5514 [PMID:18057249]
[Santin AD] [Bellone S] [Palmieri M] [Zanolini A] [Ravaggi A] [Siegel ER] [Roman JJ] [Pecorelli S] [Cannon MJ]

HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Mrz 2006 - Gynecol. Oncol.; 100(3):0090-8258 [PMID:16249018]
[Santin AD] [Bellone S] [Palmieri M] [Ravaggi A] [Romani C] [Tassi R] [Roman JJ] [Burnett A] [Pecorelli S] [Cannon MJ]

Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy.
Nov 2005 - Curr. Pharm. Des.; 11(27):1381-6128 [PMID:16248803]
[Santin AD] [Bellone S] [Roman JJ] [Burnett A] [Cannon MJ] [Pecorelli S]

Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.
Mai 2002 - Minerva Ginecol; 54(2):0026-4784 [PMID:12032451]
[Santin AD] [Bellone S] [Underwood LJ] [O'Brien TJ] [Ravaggi A] [Pecorelli S] [Cannon MJ]

Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer.
Feb 2002 - Br. J. Cancer; 86(1):0007-0920 [PMID:11857027]
[Santin AD] [Bellone S] [Ravaggi A] [Roman JJ] [Pecorelli S] [Parham GP] [Cannon MJ]